Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose.
暂无分享,去创建一个
H. Hansson | S. Thelin | J. Hultman | J. Borowiec | L. Bagge
[1] S. Thelin,et al. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. , 2008, Artificial organs.
[2] P. Venge,et al. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.
[3] W. van Oeveren,et al. Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass , 1991 .
[4] L. Hsu. Principles of heparin-coating techniques , 1991 .
[5] P. Yap. Transfusion transmitted viral infections--recent developments in blood donor screening. , 1990, Postgraduate medical journal.
[6] L. Harker,et al. Bleeding complications associated with cardiopulmonary bypass. , 1990, Blood.
[7] H. H. Harris,et al. Reoperation in the intensive care unit. , 1990, The Annals of thoracic surgery.
[8] G. Gravlee,et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. , 1990, The Journal of thoracic and cardiovascular surgery.
[9] B. Polk,et al. Transmission of Retroviruses by Transfusion of Screened Blood in Patients Undergoing Cardiac Surgery , 1989, The New England journal of medicine.
[10] M. Salo. Immunosuppressive effects of blood transfusion in anaesthesia and surgery , 1988, Acta anaesthesiologica Scandinavica. Supplementum.
[11] L. Harker. Bleeding after cardiopulmonary bypass. , 1986, The New England journal of medicine.
[12] E. Blackstone,et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.
[13] A. Carpentier,et al. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. , 1985, The Journal of thoracic and cardiovascular surgery.
[14] H. Al-Mondhiry,et al. Protamine-Induced Thrombocytopenia and Leukopenia , 1985, Thrombosis and Haemostasis.
[15] S Westaby,et al. Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.
[16] Collins Ja. Problems associated with the massive transfusion of stored blood. , 1974 .
[17] J. van der Linden,et al. Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study. , 1992, Upsala journal of medical sciences.
[18] S. Thelin,et al. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig. , 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[19] H. Lindberg,et al. Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. , 1991, Scandinavian journal of thoracic and cardiovascular surgery.
[20] M. Turina,et al. Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[21] D. Vergani,et al. Complement activation before, during and after cardiopulmonary bypass. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[22] G. Gravlee,et al. Early anticoagulation peak and rapid distribution after intravenous heparin. , 1988, Anesthesiology.
[23] P. Venge,et al. Activation of inflammatory systems during cardiopulmonary bypass. , 1988, Scandinavian journal of thoracic and cardiovascular surgery.
[24] H. Tydén,et al. Coagulation, fibrinolysis and bleeding after open-heart surgery. , 1986, Scandinavian journal of thoracic and cardiovascular surgery.
[25] R. Larsson,et al. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.